Loading data for PRLD — first visit, this takes a few seconds.

알림

Prelude Therapeutics (PRLD)

NasdaqGS: PRLD · 실시간 가격 · USD

6.59

+0.12 (1.85%)

종가 기준: Aug 27, 2026, 6:27 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

1.85% (1D)

데이터 없음

매수호가	4.74
시가총액	511.54M
매출 (ttm)	22.42M
순이익 (ttm)	-60.49M
	0.94
	-0.73
	n/a
	-8.55
P/B (ttm)	4.93
P/S (ttm)	22.77
실적 발표일	Nov 11, 2026

매도호가	8.12
거래량	415,360
평균 거래량 (20일)	463,344
시가	6.57
전일 종가	6.47
일중 범위	6.31 - 6.70
52주 범위	0.98 - 6.83
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

PRLD 소개

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated ca...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 25, 2020

직원 수 79

상장 거래소 NasdaqGS

티커 PRLD

웹사이트 https://preludetx.com

전체 기업 정보

재무 실적

2025년 Prelude Therapeutics의 매출은 12.14M로, 전년 7M 대비 73.43% 증가했습니다. 순이익은 -99.5M로, -21.76% 감소했습니다.

재무제표

어닝 서프라이즈

Prelude Therapeutics가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $4.58M 예상치 하회 $0, 및 Infinity% 전년 대비 성장.
EPS -0.14 예상치 상회 0.04, 및 65.85% 전년 대비 성장.

다음 실적 발표

Prelude Therapeutics의 실적 발표 예정일은 Nov 11, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · Stocktwits

Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential

Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.

3주 전 · Zacks

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...

1개월 전 · Zacks

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2개월 전 · Insider Monkey

Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)

Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutic...

3개월 전 · Simply Wall St.

Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Last week, you might have seen that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) released its quarterly result to...

2 페이지 중 1

Prelude Therapeutics (PRLD)